Stock DNA
Pharmaceuticals: Other
CAD 2 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.56
7.41%
-0.25
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Sep 2024)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
-70.0%
0%
-70.0%
2 Years
100.0%
0%
100.0%
3 Years
-78.57%
0%
-78.57%
4 Years
-88.24%
0%
-88.24%
5 Years
-88.0%
0%
-88.0%
BioNeutra Global Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-21.01%
EBIT Growth (5y)
14.59%
EBIT to Interest (avg)
-3.22
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.56
Sales to Capital Employed (avg)
-2.38
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.25
EV to EBIT
-6.68
EV to EBITDA
6.68
EV to Capital Employed
-1.83
EV to Sales
0.62
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Jun 2023
Shareholding Compare (%holding) 
Majority shareholders
Non Institution
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ
Sep'24
Jun'24
Change(%)
Net Sales
3.10
2.60
19.23%
Operating Profit (PBDIT) excl Other Income
-0.20
-0.40
50.00%
Interest
0.20
0.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.40
-0.80
50.00%
Operating Profit Margin (Excl OI)
-91.60%
-235.40%
14.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2024 is 19.23% vs 4.00% in Jun 2024
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2024 is 50.00% vs 0.00% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
11.40
13.40
-14.93%
Operating Profit (PBDIT) excl Other Income
-0.40
-1.40
71.43%
Interest
0.70
0.50
40.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.10
-2.90
27.59%
Operating Profit Margin (Excl OI)
-129.60%
-184.20%
5.46%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -14.93% vs -12.99% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 27.59% vs -3.57% in Dec 2022
About BioNeutra Global Corp. 
BioNeutra Global Corp.
Pharmaceuticals: Other
BioNeutra Global Corporation is engaged in the research and development, production and commercialization of food ingredients for neutraceutical, functional and mainstream foods. The Company focuses on oligosaccharides. The Company's product, VitaFiber, which is a functional and health food ingredient made from agricultural products. The Company produces VitaFiber using its processes that transforms starch molecules from agriculture cereal crops, including corn, wheat, barley, potato, or tapioca into the functional health molecules of isomalto-oligosaccharide (IMO). The Company's VitaFiber is a sweet fiber, providing low calorie and soluble prebiotic fiber for human digestive health and it is also non-genetically modified organisms (GMO), sugar-free and gluten-free. The Company's VitaFiber-IMO products include a dietary fiber, a prebiotic, manages gastrointestinal health and a low calorie health sweetener.
Company Coordinates 
Company Details
9608 - 25 Avenue NW , EDMONTON AB : T6N 1J4
Registrar Details






